Advancing Male Fertility Innovation at ASRM 2024
Inherent Biosciences d/b/a Path Fertility and its partners presented advancements in innovative fertility research at the American Society of Reproductive Medicine’s annual Congress & Expo. The 2024 conference brought together leading experts in the field to present the latest advancements in reproductive medicine and infertility. The presentations showcased new data and research in the following areas:
Economic Benefit of an Epigenetic Male Infertility Assessment : Dr. Kristin Brogaard, co-founder and CSO of Inherent Biosciences, presented data for the economic utility of SpermQT. A more comprehensive assessment of male fertility with SpermQT in the initial diagnostic workup shows cost and time savings for the patients, increased clinic margins, and significant cost savings for fertility benefits providers. Read more
A Prospective Observational Trial of SpermQT Preliminary Results: Dr. Dana Siegel, Clinical Fellow at Shady Grove Fertility, presented preliminary results from the SpermQT Prospective Observational Trial (“SPOT Study”). Early data from this prospective study suggest that despite having a higher TMC, men with an abnormal SpermQT result have fewer pregnancies after IUI than those with a normal score. Read more
AlphaSperm Supplement Induced Epigenetic Reprogramming in Sperm: Inherent Biosciences teamed up with AlphaSperm to investigate how the AlphaSperm supplement might impact sperm DNA methylation, and potentially affect fertility. The analysis provides strong evidence that sperm DNA methylation can be altered at biologically significant loci by supplementation with AlphaSperm. Read more
Future advancements:
These presentations demonstrate the company's focus on innovative, non-invasive diagnostics for the evolving needs of the reproductive healthcare sector. Future advancements will further demonstrate the clinical and economic utility of the innovative products developed and commercialized in the coming years.
Inherent Biosciences d/b/a Path Fertility, is setting new standards in male fertility research and product development with a mission to raise the standard of care in reproductive health.
